AHA: Tirzepatide Beneficial for Heart Failure With Preserved EF, Obesity
FRIDAY, Nov. 22, 2024 -- For patients with heart failure with preserved ejection fraction, tirzepatide yields a reduced risk for a composite of death from cardiovascular causes or worsening heart failure, according to a study published online Nov. 16 in the New England Journal of Medicine to coincide with the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.
Milton Packer, M.D., from the Baylor University Medical Center in Dallas, and colleagues conducted a double-blind, randomized trial involving 731 patients with heart failure, an ejection fraction of at least 50 percent, and a body mass index of at least 30 kg/m2. Participants were randomly assigned to receive tirzepatide or placebo for at least 52 weeks (364 and 367 patients, respectively) and were followed for a median of 104 weeks.
The researchers found that adjudicated death from cardiovascular causes or a worsening heart failure event occurred in 9.9 and 15.3 percent of patients in the tirzepatide and placebo groups, respectively (hazard ratio, 0.62; 95 percent confidence interval, 0.41 to 0.95; P = 0.026). Worsening heart failure events occurred in 8.0 and 14.2 percent of patients in the tirzepatide and placebo groups, respectively (hazard ratio, 0.54; 95 percent confidence interval, 0.34 to 0.85); adjudicated death from cardiovascular causes occurred in 2.2 and 1.4 percent of patients, respectively (hazard ratio, 1.58; 95 percent confidence interval, 0.52 to 4.83).
"We observed a lower risk of a composite primary end point event with tirzepatide than with placebo over a median of two years," the authors write. "This benefit was paralleled by an improvement in health status."
Several authors disclosed ties to biopharmaceutical companies, including Eli Lilly, which manufactures tirzepatide and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
First Heart Failure Hospitalization Occurs Earlier for Some Racial, Ethnic Groups
MONDAY, Sept. 8, 2025 -- First heart failure hospitalization occurs at a significantly younger age for non-Hispanic (NH) Asian, NH Black, and Hispanic adults than for NH White...
β-Blockers Not Beneficial After MI Without Reduced Left Ventricular Ejection Fraction
TUESDAY, Sept. 2, 2025 -- For patients with acute myocardial infarction (MI), beta-blockers are not beneficial in those without reduced left ventricular ejection fraction (LVEF)...
Environmental Benefit Seen With GLP-1 Receptor Agonist Use in Heart Failure
FRIDAY, Aug. 29, 2025 -- Patients with heart failure using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have less carbon dioxide equivalent (CO2e) greenhouse gas (GHG)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.